Not sure but it didn't get raised as a major issue by questioners in the conference call yesterday, a very upbeat report.
TransEnterix 2Q Loss/Shr 11c >TRXC
BY Dow Jones & Company, Inc.
— 4:05 PM ET 08/02/2017
TransEnterix, Inc. ( TRXC ) Reports Operating Results for the Second Quarter 2017 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--August 02, 2017--
TransEnterix, Inc. ( TRXC ) , a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced its operating and financial results for the second quarter of 2017.
Recent Highlights
-- The Company sold a SenhanceTM Surgical Robotic System to Saitama Medical
University International Medical Center
-- The Company submitted its 510(k) application for the Senhance Surgical
Robotic System to FDA
-- The Company raised approximately $23.2 million through an equity
financing
-- The Company refinanced its debt, securing up to $17.0 million in debt
financing
-- In July, the Senhance platform was used in the first-ever robotic
micro-laparoscopic surgeries using 3mm instruments
-- In July, the Novadaq Pinpoint Fluorescence Imaging system was used in
conjunction with the Senhance platform
"We are very pleased with the progress we made during the quarter on our key strategic priorities, including the steps taken towards achieving 510(k) clearance for the Senhance by the end of 2017," said Todd M. Pope, President and Chief Executive Officer of TransEnterix ( TRXC
Loading...
Loading...
). "We are also encouraged by the continued momentum in clinical utilization in Europe, and now globally with our sale in Japan. In addition, we have been able to leverage the open architecture of the Senhance to incorporate cutting edge technologies into the platform, setting a new standard for minimally invasive robotic surgery."
